title: Vessel dilator and kaliuretic peptide inhibit MEK 1/2 activation in human prostate cancer cells.
abstract: BACKGROUND
  Vessel dilator and kaliuretic peptide have anticancer effects in human prostate adenocarcinomas.
  
  
  METHODS
  The effect of vessel dilator, kaliuretic peptide and cyclic GMP on MEK 1/2 kinase were examined in human prostate adenocarcinoma cells.
  
  
  RESULTS
  Vessel dilator and kaliuretic peptide decreased the activation of MEK 1/2 over a concentration range of 0.01 microM to 10 microM. Vessel dilator and kaliuretic peptide (each 10 microM) inhibited the phosphorylation of MEK 1/2 kinase by 98% (p < 0.0001) and 81% (p < 0.001), respectively. The inhibition of MEK 1/2 lasted for at least two hours, where it was maximal, secondary to both peptides. Their ability to inhibit MEK 1/2 was inhibited by cyclic GMP antibody and cyclic GMP itself inhibited MEK 1/2 phosphorylation.
  
  
  CONCLUSIONS
  Vessel dilator and kaliuretic peptide both inhibit MEK 1/2 kinase mediated via cyclic GMP as part of their anticancer mechanism(s) of action.
authors.affiliation: Department of Internal Medicine, University of South Florida Cardiac Hormone Center and James A. Haley Veterans Medical Center, Tampa, Florida 33612, USA.
authors.forename: Ying
authors.initials: Y
authors.lastname: Sun
authors.forename: Ehrentraud J
authors.initials: EJ
authors.lastname: Eichelbaum
authors.forename: Hai
authors.initials: H
authors.lastname: Wang
authors.forename: David L
authors.initials: DL
authors.lastname: Vesely
mesh_terms: D000230:Adenocarcinoma / Q000201:enzymology*; D000906:Antibodies / Q000494:pharmacology; D000970:Antineoplastic Agents / Q000494:pharmacology*; D009320:Atrial Natriuretic Factor / Q000494:pharmacology*; D045744:Cell Line, Tumor; D006152:Cyclic GMP / Q000037:antagonists & inhibitors / Q000378:metabolism; D004789:Enzyme Activation; D006801:Humans; D048369:MAP Kinase Kinase 1 / Q000037:antagonists & inhibitors*; D048370:MAP Kinase Kinase 2 / Q000037:antagonists & inhibitors*; D008297:Male; D010446:Peptide Fragments / Q000494:pharmacology; D010766:Phosphorylation / Q000187:drug effects; D011471:Prostatic Neoplasms / Q000201:enzymology*; D011498:Protein Precursors / Q000494:pharmacology*
chemical_list: D000906:Antibodies; D000970:Antineoplastic Agents; D010446:Peptide Fragments; D011498:Protein Precursors; C075322:atrial natriuretic factor precursor (79-98); C054548:atrial natriuretic factor prohormone (31-67); D009320:Atrial Natriuretic Factor; D048369:MAP Kinase Kinase 1; D048370:MAP Kinase Kinase 2; D006152:Cyclic GMP